Format

Send to

Choose Destination
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):693-4. doi: 10.1016/j.ijrobp.2014.03.014.

Dose escalation, not “new biology,” can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. In reply to Rao et al.

Author information

1
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
2
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut.
3
Center for Radiological Research, Columbia University Medical Center, New York, New York.
PMID:
24929172
DOI:
10.1016/j.ijrobp.2014.03.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center